Bisphosphonates and the treatment of bone disease in the elderly

Drugs and Aging

Volumn 8, Issue 2, 1996, Pages 113-126

  Johansen, Antony ^a   Stone, Mike ^a   Rawlinson, Fiona ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Hamad Medical Coorporation Doha Qatar   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IRON; PAMIDRONIC ACID;

AGED; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MINERALIZATION; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH; REVIEW; TURNOVER TIME;

EID: 0030023323     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608020-00005     Document Type: Review

References (133)

1. Fleisch H, Felix R. Diphosphonates. Calcif Tiss Int 1979; 27: 91-4
2. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1261-4
3. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969; 165: 1264
4. Fleisch H, Neuman W. Mechanisms of calcification: role of collagen, polyphosphates and phosphatase. Am J Physiol 1961; 200: 296
5. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966; 212: 901
6. Termine JD, Posner AS. Calcium phosphate formation in vitro. Arch Biochem Biophys 1970; 140: 307-17
7. Russell RGG, Fleisch H. Pyrophosphates and diphosphonates in skeletal metabolism. Clin Orthop 1975; 108: 241-63
8. Plasmans LM, Kuypers W, Sloof T. The effect of EHDP on matrix-induced ectopic bone formation. Clin Orthop 1978; 132: 233-43
9. Ali SY, Sajdera SW, Anderson HC. Isolation and characterisation of calcifying matrix vesicles from epiphyseal cartilage. Proc Natl Acad Sci USA 1970; 67: 1513-20
10. Reynolds JJ, Morgan DB. A combined in vivo and in vitro study of the effects of diphosphonates on bone resorption. J Bone Joint Surg 1970; 52B: 796
11. Strates BS, Firschein HE, Urist MR. Alkaline phosphatase and failure of calcification under the influence of a diphosphonate. Biochimica et Biophysiac Acta 1971; 244: 121-4
12. Adami S, Salvagno G, Guarrera G, et al. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int 1986; 39: 226-9
13. Kylstra JW, Bekker PJ, Axelrod DW, et al. Risedronate in Paget's disease: preliminary results of a multi-center study. Semin Arthritis Rheum 1994; 23 (4): 272
14. Compston JE. The therapeutic use of bisphosphonates. BMJ 1994; 309: 711-5
15. Storm T, Steiniche T, Thamsborg G, et al. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 1993; 8: 199-208
16. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomised study. Am J Med 1995; 99: 36-42
17. Ott SM. Clinical effects of bisphosponates. J Bone Miner Res 1993; 8 Suppl. 2: 597-606
18. Alexandre C, Tavan P, Chappard D, et al. Intermittent administration of etidronate (Didronel) in involutional osteoporosis. In: Christiansen C, Overgaard K, editors. Osteoporosis. Copenhagen: Osteopress ApS, 1990; 1441-3
19. Fleisch H. Bisphosphonates: mechanisms of action and clinical applications. In: Peck WA, editor. Bone and mineral research, annual 1. Excerpta Medica: Amsterdam 1989: 319-57
20. Fleisch H. Diphosphonates: history and mechanisms of action. Metabol Bone Dis Relat Res 1981; 3: 279-87
21. Shinoda H, Adamek G, Felix R, et al. Structure-activity relationship of various bisphosphonates. Calcif Tissue Int 1983; 35: 87-9
22. Carano A, Teitelbaum SL, Konsek JD, et al. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990; 85: 456-61
23. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep M, et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralised matrix. Bone Miner 1986; 1: 27-40
24. Boonekamp PM, Lowik CWGM, van der Wee-Pals LJA, et al. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 1987; 2: 29-42
25. Lowik CWGM, van der Pluym G, van der Wee-Pals LJA, et al. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effects of a bisphosphonate. J Bone Min Res 1988; 2: 185-92
26. Boyce BF, Fogelman I, Ralston S, et al. Focal osteomalacia due to low dose diphosponate therapy in Paget's disease. Lancet 1984; i: 821-4
27. Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993; 342: 1459-60
28. Fenton AJ, Gutteridge DH, Kent GN, et al. Intravenous aminobisphosphonate in Paget's disease: clinical biochemical, histomorphometric and radiological responses. Clin Endocrinol 1991; 34: 197-204
29. Harink HIJ, Bijvoet OLM, Blanksma HJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 1987; 217: 79-98
30. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognised problem in gastrointestinal tolerability. Osteoporosis Int 1994; 4: 320-2
31. Mautalen CA, Casco CA, Gonsalez D, et al. Side-effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases. BMJ 1984; 288: 828-9
32. Cantrill JA, Butler HM, Anderson DC. Low dose APD for the treatment of Paget's disease of bone. Ann Rheum Dis 1986; 45: 1012-8
33. Bounameaux HM, Schleifferli J, Montani J-P, et al. Renal failure associated with intravenous bisphosphonates. Lancet 1983; i: 471
34. Yates AJP, Gray RES, Urwin GH, et al. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1985; i: 1474-7
35. Vega E, Gonzalez D, Ghiringhelli G. Intravenous APD in the treatment of Paget's bone disease. J Bone Miner Res 1987; 2 (4): 267-71
36. Delmas PD, Chapuy MC, Vignon E, et al. Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab 1982; 52: 837-44
37. Siris ES. Bisphosphonates and iritis. Lancet 1993; 341: 436-7
38. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Opthalmol 1993; 118 (2): 220-4
39. Mayordomo JI, Rivera F. Severe hypocalcaemia after treatment with diphosphonate and aminoglycoside. Ann Oncol 1993; 4: 432-5
40. Pederen-Bjergaard U, Myhre J. Severe hypocalcaemia after treatment with diphosphonate and aminoglycoside. BMJ 1991; 302: 295
41. Recker RR, Saville PD. Intestinal absorption of disodium ethane-1-hydroyl-1,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appli Pharmacol 1973; 24: 580-9
42. Yakatan GL, Poynor WJ, Talbert RL, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982; 31: 402-10
43. Daley-Yates PT, Dodwell DJ, Pongchaidecha M. The clearance and bioavilability of pamidronate in patients with breast cancer and bone metastases. Calcif Tiss Int 1991; 49: 433-5
44. Fogelman I, Smith L, Mazess R, et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986; 24: 57-62
45. Lin JH, Chen IW, Deluna FA, et al. Renal handling of aledronate in rats: an uncharacterised renal transport system. Drug Metab Dispos 1992 Jul-Aug; 20 (4): 608-13
46. Hanhijarvi H, Elomaa I, Karlsson M. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int J Clin Pharmacol Ther Toxicol 1989 Dec; 27 (12): 602-6
47. Fogelman I. Skeletal uptake of diphosphonate: a review. Eur J Nucl Med 1980; 3: 473-6
48. Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 1978; 54: 265-72
49. Makler Jr P, Charkes N. Studies of skeletal tracer kinetics IV. Optimum time delay for Tc-99m (Sn) methylene diphosphonate bone imaging. J Nucl Med 1980; 21: 641-5
50. Conrad KA, Lee SM. 1981 Clodronate kinetics and dynamics. Clin Pharmacol Ther 1981; 30: 114-20
51. Fogelman I, Pearson DW, Bessent RG, et al. A comparison of skeletal uptake of three diphosphonates by whole body retention. J Nucl Med 1981; 22: 880-3
52. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. London: Martin Dunitz, 1991
53. Frost HM. The ADFR concept revisited. Calcif Tiss Int 1984; 36: 349-53
54. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9
55. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71
56. Harris ST, Watts NB, Jackson RD, et al. The effects of four years intermittent cyclical etidronate treatment for postmenopausal osteoporosis. Am J Med 1993; 95: 557-66
57. Valkema R, Vismans F-JFE, Papapoulos SE, et al. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989; 5: 183-92
58. Papapoulos SE, Landman JO, Bijvoet OLM, et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 1992; 13 Suppl. 1: 41-9
59. Reginster JY, Lecart MP, Deroisy R, et al. Prevention of premenopausal bone loss by tiludronate. Lancet 1989; ii: 1469-71
60. Adami S, Baroni MC, Broggini M, et al. Treatment of postmenopausal osteoporosis with continuous daily oral aledronate in comparison with either placebo or intranasal samon calcitonin. Osteoporosis Int 1993; 3 Suppl. 3: 21-7
61. Recker RR, Karpf DB, Quan H, et al. Three-year treatment of osteoporosis with aledronate: effect on vertebral fracture incidence. The Endocrine Society's 77th Annual Meeting; 1995 June 14-17: Washington, DC
62. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 33: 1437-43
63. Selby PL, Rehman MT, Economou G, et al. Etidronate in male osteoporosis: evidence for a site specific action. In: Christiansen C, Riis B, editors. Proceedings of the Fourth International Symposium on Osteoporosis: 1993; Rodovre, 105-8
64. Anderson FH, Francis RM, Scane AC, et al. Cyclical etidronate in osteoporotic men - 2 year DEXA results. In: Ring EFJ, Elvins DM, Bhalla AK, editors. Current research in osteoporosis and bone mineral measurement III. London: British Institute of Radiology, 1994: 101
65. Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxyproylidene)-1,1-bisphosphonate (APD) treatment. Lancet 1988; i: 143-6
66. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid induced bone loss. Br J Rheumatol 1994; 33: 348-50
67. Adachi JD, Crannery A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994; 21: 1922-6
68. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995; 99: 235-42
69. Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung diseas: an open pilot study. Thorax 1992; 47 (11): 932-6
70. Crisp AJ. Pamidronate for Paget's disease of the bone. Br J Hosp Med 1995; 53 (3): 66-8
71. Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease. Drugs 1991; 46: 594-617
72. Smith R, Russell RGG, Bishop M. Diphosphonates and Paget's disease of bone. Lancet 1971; i: 945-7
73. Khaira MRA, Johnston CC, Altman RD, et al. Treatment of Paget's disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate. JAMA 1977; 230: 561-7
74. Altman RD. Long-term follow-up of therapy with intermittent disodium etidronate in Paget's disease of bone. Am J Med 1985; 79: 583-90
75. Gray RES, Yates AJP, Preston CJ, et al. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med 1987; 64 (245): 755-67
76. Johnston CC, Khairi MRA, Meunier PJ. Use of etidronate (EHDP) in Paget's disease of bone. Arthritis Rheum 1980; 23: 1172-6
77. Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget's disease of bone. J Endocrinol Metab 1977; 44: 96-106
78. Russell RGG, Smith R, Preston C, et al. Diphosphonates in Paget's disease. Lancet 1974; i: 894-8
79. Kantrowitz FG, Byrne M, Schiller AL, et al. Clinical and biochemical effects of diphosphonates in Paget's disease of bone. Bone 1985; 6 (2): 69-72
80. Gibbs CJ, Aaron JE, Peacock M. Osteomalacia in Paget's disease treated with short-term, high dose sodium etidronate. BMJ 1986; 292: 1227-9
81. Johnston CC, Khairi MRA, Meunier PJ. Review of fracture experience during treatment of Paget's disease of bone with etidronate sodium (EHDP). Clin Orthop 1983; 172: 186-94
82. Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 1994; 5 (6): 446-74
83. Kanis JA. Monitoring the treatment of Paget's disease with etidronate. Calcif Tissue Int 1984; 36: 623-31
84. Dewis P, Prasad BK, Anderson DC, et al. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease. Ann Rheum Dis 1985; 44: 34-8
85. Heynen G, Delwaide P, Bijvoet OLM, et al. Clinical and biological effects of low dose APD in Paget's disease of bone. Eur J Clin Invest 1982; 11: 29-35
86. Fromm GA, Plantalech L, Casco C, et al. 3-Amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) in the treatment of patients with Paget's disease of bone. Medicine 1984; 44: 245-51
87. Harink HIJ, Papapoulos SE, Blanksma HJ. Paget's disease of bone: early and late responses to three different modes of treatment with APD. BMJ 1987; 295: 1301-5
88. Ryan PJ, Sherry M, Gibson T, et al. Treatment of Paget's disease by weekly infusions of APD. Br J Rheumatol 1992; 31: 97-101
89. Gallacher SJ, Boyce BF, Patel U, et al. Clinical experience with pamidronate in the treatment of Paget's disease of bone. Ann Rheum Dis 1991; 50: 930-93
90. Pepersack T, Karmali R, Gillet C, et al. Pagets disease of bone: five regimens of pamidronate treatment. Clin Rheumatol 1994; 13 (1): 39-44
91. Stone MD, Hawthorn AB, Kerr D, et al. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD). J Bone Miner Res 1990; 5: 167-70
92. Evans AJ, Perkins AC, Wastie ML, et al. Diphosphonate space: a useful quantitive index of disease activity in patients undergoing HMDP imaging for Paget's disease. Eur J Nucl Med 1991; 18: 757-9
93. Stone MD, Marshall DH, Hosking DJ, et al. Bisphosphonate space measurement in Paget's disease of bone treated with APD. J Bone Miner Res 1992; 7: 295-301
94. Cantrill JA, Anderson DC. Treatment of Paget's disease of bone. Clin Endocrinol 1990; 32: 507-18
95. Thiebaud D, Jaeger P, Gobelet C. A single infusion of the bisphosphonate APD as treatment of Paget's disease of bone. Am J Med 1988; 85: 207-12
96. Hooper MJ, Clifton-Bligh P, Marel GM, et al. Single day intravenous pamidronate in Paget's disease. Semin Arthritis Rheum. 1994; 23 (4): 276-7
97. Siris ES. Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res 1994; 9 (3): 303-4
98. Delmas PD, Chapuy MC, Vignon E, et al. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate. Metabol Bone Dis Relat Res 1983; 4: 325-8
99. Chapuy MC, Charon SA, Meunier PJ. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate. Metab Bone Dis Relat Res 1983; 325-8
100. Hanks GW. The pharmacological treatment of bone pain. Cancer Surv 1988; 7: 87-101
101. Paterson AHG. Bone metastases in breast cancer, prostate cancer and myeloma. Bone 1987; 8 Suppl. 1: S17-S22
102. Eilon G, Mundy GR. direct resorption of bone by human breast cancer cells in vitro. Nature 1978; 276: 726-8
103. Mundy GR, Ibbotson KJ, D'Souza SM, et al. The hypercalcaemia of malignancy. Clinical implications and pathogenic mechanisms. N Engl J Med 1984; 310: 1718-27
104. Urwin GH, Percival RC, Harris S, et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721-3
105. Martin TJ, Suva LJ. Parathyroid hormone-related protein in hypercalcaemia of malignancy. Clin Endocrinol 1989; 31: 631-47
106. Bonjour JP, Rizzoli R. Pathophysiological aspects and therapeutic approaches to tumoral osteolysis and hypercalcaemia. Recent Results Cancer Res 1989; 116: 29-39
107. Bonjour JP, Philippe J, Guelpa G, et al. Bone and renal components in hypercalcaemia of malignancy and responses to a single infusion of clodronate. Bone 1988; 9: 123-30
108. Breslau NA, McGuire JL, Zerwekh JE, et al. Hypercalcaemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med 1984; 100: 1-7
109. Percival RC, Yates AJP, Gray RES, et al. The role of glucocorticoids in the management of malignant hypercalcaemia. BMJ 1984; 289: 287
110. Ralston SH, Gardner MD, Dryburgh FJ, et al. Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985; ii: 907-10
111. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; ii: 1180-2
112. Paterson AD, Kanis JA, Cameron EC, et al. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematol 1983; 54: 121-32
113. Bremmer RA, Jeliffe AM. The management of pathological fracture of the long bones from metastatic cancer. J Bone Joint Surg 1958; 40B: 652
114. Kanis JA, Yates AJP, Russell RGG. Hypercalcaemia and skeletal complications of myeloma. In: Delamore IW, editor. Multiple myeloma and other paraproteinaemias. Edinburgh: Churchill Livingstone, 1986: 307-22
115. Elomaa I, Blomqvist C, Grohn P, et al. Long term controlled trial with diphosphonate in patients with oseolytic bone metastases. Lancet 1983; i: 146-9
116. Elomaa I, Blomqvist C, Porkka L, et al. Diphosphonate for osteolytic metastases. Lancet 1985; i: 1155-6
117. Elomaa I, Blomqvist C, Porkka L, et al. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987; 8 Suppl.: 53-6
118. Paterson AHG, Powles TJ, Kanis JA, et al. Double blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65
119. Delmas PD, Charhon S, Chapuy MC, et al. Long term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 1982; 4: 163-8
120. Lahtien R, Laakso M, Palva I, et al., for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-52
121. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 1989; 116 (Suppl.): 67-72
122. van Holten-Verzantvoort AT, Bijvoet OLM, Hermans J, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet 1987; ii: 983
123. van Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, et al. The effect of supportive pamidronate treatment on aspects of quality of life with advanced breast cancer. Eur J Cancer 1991; 27; 544-9
124. Lipton A, Glover D, Harvey H, et al. Pamidronate in the treatment of bone metastases: results of 2 dose ranging trials in patients with breast or prostate cancer. Ann Oncol 1994; 5 Suppl. 7; S31-S35
125. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 1993; 19: 79-103
126. Conte PP, Giannessi PG, Latreille J, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised phase III trial. Ann Oncol 1994; 5 Suppl. 7: 41-4
127. Kanis JA, Urwin GH, Gray RES, et al. Effects of intravenous etidronate on skeletal and calcium metabolism. Am J Med 1987; 82: 55-70
128. Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcaemia of malignancy, Am J Med 1983; 74: 421-32
129. Smith JA. Palliation of painful bone metastases from prostatic cancer using sodium etidronate: a randomised, prospective double-blind controlled study. J Urol 1989; 141: 85-7
130. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9: 1397-402
131. Ketring A. Sm-153-EHDP and rhenium-186-HEDP as bone therapeutic radio-pharmaceuticals. Int J Rad Appl Instrum B 1987; 14: 223-32
132. Faranghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33: 1451-8
133. Maxon HRI, Scroder LE, Hertzberg VS, et al. Rhenium-186(sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991; 32: 1877-81